This post was originally published on this site After first rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now recommended the use of Adcetris (brentuximab vedotin) as a second-line therapy for patients with CD30-positive cutaneous T-cell lymphomas (CTCL). This means that CTCL patients living in the U.K. may now have access to Adcetris…
This post was originally published on this site Combining anti-PD-L1 immunotherapies with agents that inhibit the DNA damage response (DDR) significantly enhances anti-tumor immunity and leads to rapid tumor disappearance in mouse models of small cell lung cancer (SCLC), a study reports. These preclinical findings suggest that adding DDR inhibitors, such as Lynparza (olaparib) or prexasertib, to immune checkpoint…
This post was originally published on this site Frying oil that has repeatedly been reheated to high temperatures — as can take place in deep frying of foods — may cause genetic changes that trigger the growth and spread of breast cancer, a study in a mouse model of the disease reports. The study, “Thermally…
This post was originally published on this site AVP-786, an investigational oral therapy, significantly relieved agitated behaviors among patients with Alzheimer’s dementia, according to preliminary data from a worldwide Phase 3 trial by Avanir Pharmaceuticals. The treatment candidate was designed as a second-generation version of Nuedexta, a two-drug combo approved for pseudobulbar affect. AVP-786 is…
This post was originally published on this site hi there i m testing this space for ads. hi there i m testing this space for ads. hi there i m testing this space for ads. hi there i m testing this space for ads. hi there i m testing this space for ads. why not…
This post was originally published on this site Combining the immune checkpoint inhibitor Keytruda (pembrolizumab) with either a PARP inhibitor, chemotherapy, or hormone therapy led to promising signs of activity in metastatic castration-resistant prostate cancer (mCRPC) patients in a Phase 1b/2 trial, Merck — Keytruda’s developer — announced. The findings were presented at the 2019…
This post was originally published on this site Patients with follicular lymphoma and marginal zone lymphoma who failed at least one prior therapy live significantly longer — more than two years — without their disease worsening when treated with a combination of Revlimid (lenalidomide) and Rituxan (rituximab), compared to Rituxan alone, a Phase 3 trial shows. The combination was also superior…
This post was originally published on this site Adding SOTIO’s ovarian cancer immunotherapy DCVAC/OvCa to standard second-line chemotherapy significantly extends the lives of women with advanced ovarian cancer who initially responded to their first-line chemotherapy, a Phase 2 trial shows. The combination also extended the time patients lived without signs of disease worsening compared with…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on venetoclax’s multiple myeloma trials after new safety concerns were raised during a review of the BELLINI Phase 3 trial (NCT02755597). This means that all ongoing clinical trials assessing AbbVie‘s venetoclax in multiple myeloma can no…
This post was originally published on this site A combination of the immunotherapies Keytruda (pembrolizumab) and CRS-207 is safe, but has no evidence of clinical activity in adults with malignant pleural mesothelioma who failed prior lines of therapy, a Phase 2 study shows. Based on the findings and on additional data from CRS-207’s program, the therapy’s clinical…
